When the big end of town who invest in biotechnology companies recognize the peak revenue opportunities for a first-in-class CPACS, do you or anyone else think they will sit idle on the sidelines and miss out?
Seems like it might even be part of RACs plan - to tip off one of the big-time biotech investment firms when...oh, I don't know, maybe when CPACS is validated in P1a/b.
RAC will probably also be at international conferences talking about the world-first by then too. Investment organizations that frequent those conferences probably want to miss out too.
These people love making money. In biotech, you make the most money from first-in-class platform plays.
CPACS: Research, Results, Market Comparisons, and Valuations, page-192
-
- There are more pages in this discussion • 116 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.045(3.01%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.45 | $62.74K | 42.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14110 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 666 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |